Ropes & Gray advised Sanofi in connection with Toronto-based Zucara Therapeutics’ $20 million Series B financing. Diabetes life sciences company Zucara is developing a once-daily therapeutic, ZT-01, to prevent hypoglycemia in people with diabetes. Proceeds from the investment will fund the remainder of Zucara’s ongoing Phase 2a clinical trial to develop a once-weekly version of ZT-01. As part of the agreement, Sanofi will also receive an exclusive right of first negotiation. The transaction was announced on November 12.
The Ropes & Gray team included venture capital & emerging companies and life sciences licensing associate Daniel Freshman, venture capital & emerging companies and life sciences licensing associate Philip Wu and life sciences licensing partner Abigail Gregor.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.